COST EFFECTIVENESS ANALYSIS OF ALEMTUZUMAB AS A TREATMENT OPTION FOR PATIENTS WITH MULTIPLE SCLEROSIS IN GREECE

被引：1
|
作者：
Kourkoulas, N. [1 ]
Athanasakis, K. [1 ]
Kyriopoulos, J. [1 ]
机构：
[1] Natl Sch Publ Hlth, Athens, Greece
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.2025
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND59
引用
收藏
页码：S339 / S339
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England
    Hettle, Robert
    Harty, Gerard
    Wong, Schiffon L.
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (07) : 676 - 686
  • [42] In depth analysis of B cells in multiple sclerosis patients after long-term treatment with Alemtuzumab
    Marsh-Wakefield, Felix
    Juillard, Pierre
    Ashhurst, Thomas
    McGuire, Helen
    Byrne, Scott
    Grau, Georges
    Hawke, Simon
    NEUROLOGY, 2020, 94 (15)
  • [43] Effect of Alemtuzumab (LEMTRADA®) treatment on the peripheral immune repertoire in multiple sclerosis patients
    Barman, S.
    Scheffler, A.
    Ruck, T.
    Lehrich, C.
    Coordt, A.
    Sporkmann, P.
    Wiendl, H.
    Meuth, S.
    Hartung, H. -P.
    Melzer, N.
    Goebels, N.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 933 - 933
  • [44] Impact of Immunodepleting Treatment with Alemtuzumab on the Peripheral Treg Compartment in Patients with Multiple Sclerosis
    Haas, Juergen
    Schwarz, Alexander
    Korporal-Kuhnke, Mirjam
    Jarius, Sven
    Meuth, Sven
    Wildemann, Brigitte
    NEUROLOGY, 2018, 90
  • [45] Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study
    Kazakou, Paraskevi
    Tzanetakos, Dimitrios
    Vakrakou, Aigli G.
    Tzartos, John S.
    Evangelopoulos, Maria-Eleptheria
    Anagnostouli, Maria
    Stathopoulos, Panos
    Kassi, Georgia N.
    Stefanis, Leonidas
    Kilidireas, Constantinos
    Zapanti, Evangelia
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (06) : 2885 - 2894
  • [46] Are statins a treatment option for multiple sclerosis?
    Neuhaus, O
    Stüve, O
    Zamvil, SS
    Hartung, HP
    LANCET NEUROLOGY, 2004, 3 (06): : 369 - 371
  • [47] Tenofovir as a treatment option for multiple sclerosis
    Torkildsen, Oivind
    Myhr, Kjell-Morten
    Skogen, Vegard
    Steffensen, Linn Hofsoy
    Bjornevik, Kjetil
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 46
  • [48] Different infusion reaktions of two treatment schedules with alemtuzumab in patients with multiple sclerosis
    Von Wussow, Peter
    Schreiber, Martin
    NEUROLOGY, 2017, 88
  • [49] Effect of Alemtuzumab (LEMTRADA®) Treatment on the Peripheral Immune Repertoire in Multiple Sclerosis Patients
    Barman, Sumanta
    Scheffler, Armin
    Ruck, Tobias
    Lehrich, Christoph
    Balz, Vera
    Wiendl, Heinz
    Meuth, Sven
    Hartung, Hans-Peter
    Melzer, Nico
    Goebels, Norbert
    NEUROLOGY, 2020, 94 (15)
  • [50] Impact of immunodepleting treatment with alemtuzumab on the peripheral Treg compartment in patients with multiple sclerosis
    Haas, J.
    Korporal-Kuhnke, M.
    Jarius, S.
    Wildemann, B.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 672 - 673
12345